Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter century kept Wall Street in check.

U.S. stocks ended mixed Thursday, with the Dow losing ground as sharp moves lower in healthcare stocks shaped a volatile ...

U.S. stocks are holding steadier in the final day of trading for their holiday-shortened week. The S&P 500 rose 0.2% Thursday ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose weight. The company is hoping to bring the first GLP-1 weight-loss pill to ...

Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed ...